All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with
hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Sustained virological response based on the week 4 response in
hepatitis C virus genotype 1 patients treated with peginterferons [alpha]-2a and [alpha]-2b, plus ribavirin.
Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience.
IL-28B genetic variation, gender, age, jaundice,
hepatitis C virus genotype, and hepatitis B virus and HIV co-infection in spontaneous clearance of hepatitis C virus.
Hepatitis C Virus Genotype 7, a New Genotype Originating from Central Africa.
Hepatitis C virus genotype distribution in Egyptian diabetic patients: a preliminary study.
The POLARIS-1 study has evaluated Vosevi for 12 weeks in adults with
hepatitis C virus genotype 1, 2, 3, 4, 5 or 6 with or without compensated cirrhosis who had failed prior treatment with an NS5A inhibitor-containing regimen.
Effect of interferon plus ribavirin therapy on
hepatitis C virus genotype 3 patients from Pakistan: treatment response, side effects and future prospective.
According to Inoue et al., in blood transfusion unit about 2.1% were infected with HCV.4 In Indonesia, a study in several hospitals of Jakarta, reported that
hepatitis C virus genotype 1 is the most prevalent about 72.7%, composed of subtype 1b 47.3%, subtype 1c 18.7% and subtype 1a 6.7%.5
Hepatitis C virus genotype subtypes prevalence within transmission route groups Presentation of HCV-genotype Sig.
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic
hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial.